Paper8740978
In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide.
Cipolla B and 6 others. Urol Res, 1996. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide. Papers, record 8740978. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8740978
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Polyamines | Major topic |
| Prostatic Neoplasms | Major topic |
| Animals | |
| Antineoplastic Agents | |
| Antineoplastic Agents, Alkylating | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Cyclophosphamide | |
| Dose-Response Relationship, Drug | |
| Drug Synergism | |
| Drug Therapy, Combination | |
| Eflornithine | |
| Lung Neoplasms | |
| Male | |
| Metronidazole | |
| Neomycin | |
| Oxidoreductases Acting on CH-NH Group Donors | |
| Protein Synthesis Inhibitors | |
| Putrescine | |
| Rats | |
| Rats, Inbred Strains | |
| Survival Rate |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1942311 | The growth of MAT-LyLu rat prostatic adenocarcinoma can be prevented in vivo by polyamine deprivation. | J Urol | 1991 | https://conductscience.org/library/papers/1942311 | PubMed |
| 2 | 7300587 | Red cell free polyamine concentrations in patients on maintenance hemodialysis. | Life Sci | 1981 | https://conductscience.org/library/papers/7300587 | PubMed |
| 3 | 350276 | Polyamines in rapid growth and cancer. | Biochim Biophys Acta | 1978 | https://conductscience.org/library/papers/350276 | PubMed |
| 4 | 1444206 | Polyamine deprivation enhances antitumoral efficacy of chemotherapy. | Anticancer Res | 1992 | https://conductscience.org/library/papers/1444206 | PubMed |
| 5 | 3314999 | Prostate tumor progression and metastasis. | Biochim Biophys Acta | 1987 | https://conductscience.org/library/papers/3314999 | PubMed |
| 6 | 7041538 | Polyamines in mammalian tumors. Part I. | Adv Cancer Res | 1981 | https://conductscience.org/library/papers/7041538 | PubMed |
| 7 | 7040832 | Interconversion, catabolism and elimination of the polyamines. | Med Biol | 1981 | https://conductscience.org/library/papers/7040832 | PubMed |
| 8 | 3123052 | Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. | Cancer Res | 1988 | https://conductscience.org/library/papers/3123052 | PubMed |
| 9 | 1700142 | Erythrocyte polyamine levels in human prostatic carcinoma. | J Urol | 1990 | https://conductscience.org/library/papers/1700142 | PubMed |
| 10 | 7689970 | Polyamines and prostatic carcinoma: clinical and therapeutic implications. | Eur Urol | 1993 | https://conductscience.org/library/papers/7689970 | PubMed |
| 11 | 3530115 | Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. | Anticancer Res | 1986 | https://conductscience.org/library/papers/3530115 | PubMed |
| 12 | 2116224 | Endogenous and exogenous polyamines in support of tumor growth. | Cancer Res | 1990 | https://conductscience.org/library/papers/2116224 | PubMed |
| 13 | 2028560 | Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate. | Urol Res | 1991 | https://conductscience.org/library/papers/2028560 | PubMed |
| 14 | 7508520 | Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients. | J Urol | 1994 | https://conductscience.org/library/papers/7508520 | PubMed |
| 15 | 3118759 | Inhibition of polyamine oxidase improves the antitumoral effect of ornithine decarboxylase inhibitors. | Anticancer Res | 1987 | https://conductscience.org/library/papers/3118759 | PubMed |
| 16 | 2924329 | Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models. | Cancer Immunol Immunother | 1989 | https://conductscience.org/library/papers/2924329 | PubMed |
| 17 | 2018351 | Inhibition of the growth of U-251 human glioblastoma in nude mice by polyamine deprivation. | Anticancer Res | 1991 | https://conductscience.org/library/papers/2018351 | PubMed |
| 18 | 2495754 | The gastrointestinal tract as polyamine source for tumor growth. | Anticancer Res | 1989 | https://conductscience.org/library/papers/2495754 | PubMed |
| 19 | 6466732 | In vitro studies on the entry of polyamines into normal red blood cells. | Biochimie | 1984 | https://conductscience.org/library/papers/6466732 | PubMed |
| 20 | 3965702 | N-2,3-Butadienyl-1,4-butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase. | J Med Chem | 1985 | https://conductscience.org/library/papers/3965702 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8740978
GET https://conductscience.org/api/papers/v1/8740978/references?page=2